Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).

Chronic Lymphocytic Leukemia (CLL) is the most prevalent leukemia in Western countries and is notable for its variable clinical course. This variability is partly reflected by the mutational status of IGHV genes. Many CLL samples have been studied in recent years by next-generation sequencing. These...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Julia González-Rincón, José A Garcia-Vela, Sagrario Gómez, Belén Fernández-Cuevas, Sara Nova-Gurumeta, Nuria Pérez-Sanz, Miguel Alcoceba, Marcos González, Eduardo Anguita, Javier López-Jiménez, Eva González-Barca, Lucrecia Yáñez, Ernesto Pérez-Persona, Javier de la Serna, Miguel Fernández-Zarzoso, Guillermo Deben, Francisco J Peñalver, María C Fernández, Jaime Pérez de Oteyza, M Ángeles Andreu, M Ángeles Ruíz-Guinaldo, Raquel Paz-Arias, M Dolores García-Malo, Valle Recasens, Rosa Collado, Raúl Córdoba, Belén Navarro-Matilla, Margarita Sánchez-Beato, José A García-Marco
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/792f13e07f4d443d9b3335081a4b1ee4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:792f13e07f4d443d9b3335081a4b1ee4
record_format	dspace
spelling	oai:doaj.org-article:792f13e07f4d443d9b3335081a4b1ee42021-12-02T20:06:18ZGenomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).1932-620310.1371/journal.pone.0257353https://doaj.org/article/792f13e07f4d443d9b3335081a4b1ee42021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0257353https://doaj.org/toc/1932-6203Chronic Lymphocytic Leukemia (CLL) is the most prevalent leukemia in Western countries and is notable for its variable clinical course. This variability is partly reflected by the mutational status of IGHV genes. Many CLL samples have been studied in recent years by next-generation sequencing. These studies have identified recurrent somatic mutations in NOTCH1, SF3B1, ATM, TP53, BIRC3 and others genes that play roles in cell cycle, DNA repair, RNA metabolism and splicing. In this study, we have taken a deep-targeted massive sequencing approach to analyze the impact of mutations in the most frequently mutated genes in patients with CLL enrolled in the REM (rituximab en mantenimiento) clinical trial. The mutational status of our patients with CLL, except for the TP53 gene, does not seem to affect the good results obtained with maintenance therapy with rituximab after front-line FCR treatment.Julia González-RincónJosé A Garcia-VelaSagrario GómezBelén Fernández-CuevasSara Nova-GurumetaNuria Pérez-SanzMiguel AlcocebaMarcos GonzálezEduardo AnguitaJavier López-JiménezEva González-BarcaLucrecia YáñezErnesto Pérez-PersonaJavier de la SernaMiguel Fernández-ZarzosoGuillermo DebenFrancisco J PeñalverMaría C FernándezJaime Pérez de OteyzaM Ángeles AndreuM Ángeles Ruíz-GuinaldoRaquel Paz-AriasM Dolores García-MaloValle RecasensRosa ColladoRaúl CórdobaBelén Navarro-MatillaMargarita Sánchez-BeatoJosé A García-MarcoPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 9, p e0257353 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Julia González-Rincón José A Garcia-Vela Sagrario Gómez Belén Fernández-Cuevas Sara Nova-Gurumeta Nuria Pérez-Sanz Miguel Alcoceba Marcos González Eduardo Anguita Javier López-Jiménez Eva González-Barca Lucrecia Yáñez Ernesto Pérez-Persona Javier de la Serna Miguel Fernández-Zarzoso Guillermo Deben Francisco J Peñalver María C Fernández Jaime Pérez de Oteyza M Ángeles Andreu M Ángeles Ruíz-Guinaldo Raquel Paz-Arias M Dolores García-Malo Valle Recasens Rosa Collado Raúl Córdoba Belén Navarro-Matilla Margarita Sánchez-Beato José A García-Marco Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).
description	Chronic Lymphocytic Leukemia (CLL) is the most prevalent leukemia in Western countries and is notable for its variable clinical course. This variability is partly reflected by the mutational status of IGHV genes. Many CLL samples have been studied in recent years by next-generation sequencing. These studies have identified recurrent somatic mutations in NOTCH1, SF3B1, ATM, TP53, BIRC3 and others genes that play roles in cell cycle, DNA repair, RNA metabolism and splicing. In this study, we have taken a deep-targeted massive sequencing approach to analyze the impact of mutations in the most frequently mutated genes in patients with CLL enrolled in the REM (rituximab en mantenimiento) clinical trial. The mutational status of our patients with CLL, except for the TP53 gene, does not seem to affect the good results obtained with maintenance therapy with rituximab after front-line FCR treatment.
format	article
author	Julia González-Rincón José A Garcia-Vela Sagrario Gómez Belén Fernández-Cuevas Sara Nova-Gurumeta Nuria Pérez-Sanz Miguel Alcoceba Marcos González Eduardo Anguita Javier López-Jiménez Eva González-Barca Lucrecia Yáñez Ernesto Pérez-Persona Javier de la Serna Miguel Fernández-Zarzoso Guillermo Deben Francisco J Peñalver María C Fernández Jaime Pérez de Oteyza M Ángeles Andreu M Ángeles Ruíz-Guinaldo Raquel Paz-Arias M Dolores García-Malo Valle Recasens Rosa Collado Raúl Córdoba Belén Navarro-Matilla Margarita Sánchez-Beato José A García-Marco
author_facet	Julia González-Rincón José A Garcia-Vela Sagrario Gómez Belén Fernández-Cuevas Sara Nova-Gurumeta Nuria Pérez-Sanz Miguel Alcoceba Marcos González Eduardo Anguita Javier López-Jiménez Eva González-Barca Lucrecia Yáñez Ernesto Pérez-Persona Javier de la Serna Miguel Fernández-Zarzoso Guillermo Deben Francisco J Peñalver María C Fernández Jaime Pérez de Oteyza M Ángeles Andreu M Ángeles Ruíz-Guinaldo Raquel Paz-Arias M Dolores García-Malo Valle Recasens Rosa Collado Raúl Córdoba Belén Navarro-Matilla Margarita Sánchez-Beato José A García-Marco
author_sort	Julia González-Rincón
title	Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).
title_short	Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).
title_full	Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).
title_fullStr	Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).
title_full_unstemmed	Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).
title_sort	genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with fcr and rituximab maintenance (rem).
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/792f13e07f4d443d9b3335081a4b1ee4
work_keys_str_mv	AT juliagonzalezrincon genomicmutationprofileinprogressivechroniclymphocyticleukemiapatientspriortofirstlinechemoimmunotherapywithfcrandrituximabmaintenancerem AT joseagarciavela genomicmutationprofileinprogressivechroniclymphocyticleukemiapatientspriortofirstlinechemoimmunotherapywithfcrandrituximabmaintenancerem AT sagrariogomez genomicmutationprofileinprogressivechroniclymphocyticleukemiapatientspriortofirstlinechemoimmunotherapywithfcrandrituximabmaintenancerem AT belenfernandezcuevas genomicmutationprofileinprogressivechroniclymphocyticleukemiapatientspriortofirstlinechemoimmunotherapywithfcrandrituximabmaintenancerem AT saranovagurumeta genomicmutationprofileinprogressivechroniclymphocyticleukemiapatientspriortofirstlinechemoimmunotherapywithfcrandrituximabmaintenancerem AT nuriaperezsanz genomicmutationprofileinprogressivechroniclymphocyticleukemiapatientspriortofirstlinechemoimmunotherapywithfcrandrituximabmaintenancerem AT miguelalcoceba genomicmutationprofileinprogressivechroniclymphocyticleukemiapatientspriortofirstlinechemoimmunotherapywithfcrandrituximabmaintenancerem AT marcosgonzalez genomicmutationprofileinprogressivechroniclymphocyticleukemiapatientspriortofirstlinechemoimmunotherapywithfcrandrituximabmaintenancerem AT eduardoanguita genomicmutationprofileinprogressivechroniclymphocyticleukemiapatientspriortofirstlinechemoimmunotherapywithfcrandrituximabmaintenancerem AT javierlopezjimenez genomicmutationprofileinprogressivechroniclymphocyticleukemiapatientspriortofirstlinechemoimmunotherapywithfcrandrituximabmaintenancerem AT evagonzalezbarca genomicmutationprofileinprogressivechroniclymphocyticleukemiapatientspriortofirstlinechemoimmunotherapywithfcrandrituximabmaintenancerem AT lucreciayanez genomicmutationprofileinprogressivechroniclymphocyticleukemiapatientspriortofirstlinechemoimmunotherapywithfcrandrituximabmaintenancerem AT ernestoperezpersona genomicmutationprofileinprogressivechroniclymphocyticleukemiapatientspriortofirstlinechemoimmunotherapywithfcrandrituximabmaintenancerem AT javierdelaserna genomicmutationprofileinprogressivechroniclymphocyticleukemiapatientspriortofirstlinechemoimmunotherapywithfcrandrituximabmaintenancerem AT miguelfernandezzarzoso genomicmutationprofileinprogressivechroniclymphocyticleukemiapatientspriortofirstlinechemoimmunotherapywithfcrandrituximabmaintenancerem AT guillermodeben genomicmutationprofileinprogressivechroniclymphocyticleukemiapatientspriortofirstlinechemoimmunotherapywithfcrandrituximabmaintenancerem AT franciscojpenalver genomicmutationprofileinprogressivechroniclymphocyticleukemiapatientspriortofirstlinechemoimmunotherapywithfcrandrituximabmaintenancerem AT mariacfernandez genomicmutationprofileinprogressivechroniclymphocyticleukemiapatientspriortofirstlinechemoimmunotherapywithfcrandrituximabmaintenancerem AT jaimeperezdeoteyza genomicmutationprofileinprogressivechroniclymphocyticleukemiapatientspriortofirstlinechemoimmunotherapywithfcrandrituximabmaintenancerem AT mangelesandreu genomicmutationprofileinprogressivechroniclymphocyticleukemiapatientspriortofirstlinechemoimmunotherapywithfcrandrituximabmaintenancerem AT mangelesruizguinaldo genomicmutationprofileinprogressivechroniclymphocyticleukemiapatientspriortofirstlinechemoimmunotherapywithfcrandrituximabmaintenancerem AT raquelpazarias genomicmutationprofileinprogressivechroniclymphocyticleukemiapatientspriortofirstlinechemoimmunotherapywithfcrandrituximabmaintenancerem AT mdoloresgarciamalo genomicmutationprofileinprogressivechroniclymphocyticleukemiapatientspriortofirstlinechemoimmunotherapywithfcrandrituximabmaintenancerem AT vallerecasens genomicmutationprofileinprogressivechroniclymphocyticleukemiapatientspriortofirstlinechemoimmunotherapywithfcrandrituximabmaintenancerem AT rosacollado genomicmutationprofileinprogressivechroniclymphocyticleukemiapatientspriortofirstlinechemoimmunotherapywithfcrandrituximabmaintenancerem AT raulcordoba genomicmutationprofileinprogressivechroniclymphocyticleukemiapatientspriortofirstlinechemoimmunotherapywithfcrandrituximabmaintenancerem AT belennavarromatilla genomicmutationprofileinprogressivechroniclymphocyticleukemiapatientspriortofirstlinechemoimmunotherapywithfcrandrituximabmaintenancerem AT margaritasanchezbeato genomicmutationprofileinprogressivechroniclymphocyticleukemiapatientspriortofirstlinechemoimmunotherapywithfcrandrituximabmaintenancerem AT joseagarciamarco genomicmutationprofileinprogressivechroniclymphocyticleukemiapatientspriortofirstlinechemoimmunotherapywithfcrandrituximabmaintenancerem
_version_	1718375366976864256

Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).

Ejemplares similares